In this podcast, Dr. Petros Grivas and Dr. Marianne Dubard-Gault discuss what people with bladder cancer and their families should know about genetic testing.
In this “Cancer in My Community” post, Dr. Krittiya Korphaisarn shares what cancer is like in Thailand, including how cancer is treated and why the Thai government launched a genetic testing initiative in the country.
Read research from the August 2022 session of the ASCO Plenary Series, which features a study that evaluated how common it is for people with lung cancer to have inherited genetic mutations known to increase cancer risk.
In this podcast, experts discuss what people with early-stage lung cancer should know about molecular testing, including what it is, how it may be used in guiding treatment decisions, and several recent studies about its role in treatment planning.
At-home DNA tests have become increasingly popular in recent years. But are they actually helpful for detecting cancer risk? In this post, learn about at-home DNA tests for cancer risk and why it’s always best to get genetic screening done through your health care provider.
Lung cancer survivor Amanda Nerstad shares what it was like receiving a stage 4 diagnosis at age 39, the role genomic testing played in prolonging her quality of life, and how she and her family cope with the diagnosis.
In this podcast, Dr. Funda Meric-Bernstam and Dr. Mark Robson discuss a new ASCO provisional clinical opinion on somatic genomic testing in people with metastatic or advanced cancer, including what it is and how it impacts cancer treatment.
In this post, Dr. Andrea Walens shares what it was like learning she had a genetic mutation that put her at an increased risk of breast cancer and why she decided to get a prophylactic double mastectomy to help prevent the development of cancer in the future.
Research from ASCO’s 2022 Genitourinary Cancers Symposium features a study on predicting the risk of developing and dying from metastatic prostate cancer in a diverse population.
In this podcast, 4 experts discuss the first-ever targeted therapies approved for people with non-small cell lung cancer with an epidermal growth factor receptor (EGFR) exon 20 insertion mutation, including how they work and what they mean for people with this type of cancer.
